Oxaliplatin, a platinum-based antineoplastic agent used in cancer chemotherapy, is able to promote apoptosis of tumor cells by inhibiting DNA synthesis, inducing DNA double-strand cross-linking, and blocking DNA replication and transcription processes.17 Previous bioinformatics analysis revealed that MEIS1 was significantly downregulated in CRC samples with oxaliplatin resistance (Fig. 1c), so we suspected that MEIS1 might be involved in the reactivity of CRC cells to oxaliplatin. This evidence concerns the gene MEIS1 and colorectal carcinoma.